| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Khosrow Rezvani | |
| Sanam Sane | |||
| P2860 | cites work | Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and MDM2 | Q24293517 |
| BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction | Q24295121 | ||
| The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2 | Q24296502 | ||
| PML regulates p53 stability by sequestering Mdm2 to the nucleolus | Q24296743 | ||
| Molecular basis of Pirh2-mediated p53 ubiquitylation | Q24319435 | ||
| ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways | Q24321528 | ||
| miR-661 downregulates both Mdm2 and Mdm4 to activate p53. | Q37475492 | ||
| Murine double minute 2: p53-independent roads lead to genome instability or death | Q37485238 | ||
| The multiple levels of regulation by p53 ubiquitination | Q37526379 | ||
| The regulation of MDM2 oncogene and its impact on human cancers | Q37599707 | ||
| Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells | Q37680211 | ||
| Comparative binding of p53 to its promoter and DNA recognition elements. | Q51503955 | ||
| CHIP chaperones wild type p53 tumor suppressor protein. | Q51578869 | ||
| p27: tumor suppressor and oncogene ...? | Q60614882 | ||
| MDM2 gene amplification in bone and soft‐tissue tumors: Association with tumor progression in differentiated adipose‐tissue tumors | Q71820198 | ||
| Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas | Q72769128 | ||
| The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin | Q72776855 | ||
| Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination | Q79984349 | ||
| CHIP participates in protein triage decisions by preferentially ubiquitinating Hsp70-bound substrates | Q24338386 | ||
| Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development | Q24628811 | ||
| The first 30 years of p53: growing ever more complex | Q24645732 | ||
| Ribosomal Protein L11 Negatively Regulates Oncoprotein MDM2 and Mediates a p53-Dependent Ribosomal-Stress Checkpoint Pathway | Q24648370 | ||
| Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer | Q24670460 | ||
| Clinical Overview of MDM2/X-Targeted Therapies | Q26767402 | ||
| Regulation of Mutant p53 Protein Expression | Q26770579 | ||
| Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation | Q27322960 | ||
| Regulation of p53 stability by Mdm2 | Q27860744 | ||
| A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. | Q27935265 | ||
| Surfing the p53 network | Q28032484 | ||
| Functions of the MDM2 oncoprotein | Q28138115 | ||
| MDM2--master regulator of the p53 tumor suppressor protein | Q28138926 | ||
| Characterization of human constitutive photomorphogenesis protein 1, a RING finger ubiquitin ligase that interacts with Jun transcription factors and modulates their transcriptional activity | Q28180384 | ||
| Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase | Q28240243 | ||
| c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer | Q28242811 | ||
| The ubiquitin ligase COP1 is a critical negative regulator of p53 | Q28258057 | ||
| Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity | Q28270986 | ||
| COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas | Q28288506 | ||
| p53 mutations in human cancers | Q28302973 | ||
| Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation | Q28609772 | ||
| The p53-mdm-2 autoregulatory feedback loop | Q28609811 | ||
| Mapping of the p53 and mdm-2 Interaction Domains | Q28609886 | ||
| Blinded by the Light: The Growing Complexity of p53 | Q29547590 | ||
| Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 | Q29614430 | ||
| p53 and metabolism | Q29617084 | ||
| Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. | Q29976922 | ||
| Chaperone functions of the E3 ubiquitin ligase CHIP. | Q30362083 | ||
| Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. | Q33440643 | ||
| Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis | Q33601591 | ||
| The ARF/p53 pathway | Q33840421 | ||
| Gambogic acid, a natural product inhibitor of Hsp90 | Q33870322 | ||
| microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network. | Q33883240 | ||
| E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia | Q33903412 | ||
| p53 N-terminal phosphorylation: a defining layer of complex regulation | Q36401999 | ||
| Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition | Q36499146 | ||
| 14-3-3σ Positively Regulates p53 and Suppresses Tumor Growth | Q36549508 | ||
| MDM2 inhibitors for cancer therapy | Q36663493 | ||
| Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy | Q36674097 | ||
| Three faces of mortalin: a housekeeper, guardian and killer | Q36692181 | ||
| The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression | Q36697766 | ||
| Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. | Q36710840 | ||
| Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. | Q36736987 | ||
| HSP70 binding sites in the tumor suppressor protein p53. | Q36872778 | ||
| p28, a first in class peptide inhibitor of cop1 binding to p53. | Q36959166 | ||
| COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis. | Q37162398 | ||
| The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies | Q37239907 | ||
| Reflecting on 25 years with MYC. | Q37333643 | ||
| Stress-dependent Daxx-CHIP interaction suppresses the p53 apoptotic program | Q37343994 | ||
| Regulation of the MDM2-p53 pathway by the nucleolar protein CSIG in response to nucleolar stress | Q37394276 | ||
| Suppression of the mouse double minute 4 gene causes changes in cell cycle control in a human mesothelial cell line responsive to ultraviolet radiation exposure | Q37463604 | ||
| Stress signals utilize multiple pathways to stabilize p53 | Q33963268 | ||
| MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation | Q34016183 | ||
| The p53 orchestra: Mdm2 and Mdmx set the tone | Q34020353 | ||
| Role of Pirh2 in mediating the regulation of p53 and c-Myc | Q34085616 | ||
| Polyubiquitination of p53 by a ubiquitin ligase activity of p300. | Q34190044 | ||
| Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma | Q34268395 | ||
| Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. | Q34283106 | ||
| Control of human PIRH2 protein stability: involvement of TIP60 and the proteosome | Q34287238 | ||
| The role of tetramerization in p53 function | Q34290217 | ||
| Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. | Q34368432 | ||
| MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame | Q34369223 | ||
| Making sense of ubiquitin ligases that regulate p53 | Q34503497 | ||
| The pathological response to DNA damage does not contribute to p53-mediated tumour suppression | Q34564198 | ||
| An oncogene-induced DNA damage model for cancer development | Q34759268 | ||
| Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. | Q34761024 | ||
| Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells | Q34989395 | ||
| CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. | Q35006610 | ||
| Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. | Q35012244 | ||
| Awakening guardian angels: drugging the p53 pathway | Q35014385 | ||
| TP53 mutation in colorectal cancer | Q35078750 | ||
| TP53 in hematological cancer: low incidence of mutations with significant clinical relevance | Q35078753 | ||
| TP53 and ovarian cancer | Q35078757 | ||
| MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination | Q35084991 | ||
| Improving cancer therapy by non-genotoxic activation of p53. | Q35123468 | ||
| Functional significance of point mutations in stress chaperone mortalin and their relevance to Parkinson disease. | Q35221600 | ||
| miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. | Q35624504 | ||
| The importance of p53 location: nuclear or cytoplasmic zip code? | Q35639326 | ||
| Regulating the p53 system through ubiquitination | Q35691573 | ||
| CHIP: a link between the chaperone and proteasome systems | Q35759085 | ||
| MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy | Q35848425 | ||
| Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia | Q35849887 | ||
| Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells | Q35916594 | ||
| Post-translational modification of p53 in tumorigenesis | Q35930703 | ||
| 14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability. | Q35979769 | ||
| MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy | Q36047902 | ||
| DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. | Q37684761 | ||
| p53-based cancer therapy | Q37750115 | ||
| The tumor suppressor p53: from structures to drug discovery | Q37762069 | ||
| Translating p53 into the clinic. | Q37803120 | ||
| Recent advances in the therapeutic perspectives of Nutlin-3. | Q37851525 | ||
| p53 regulation by ubiquitin | Q37882073 | ||
| Spotlight on the role of COP1 in tumorigenesis | Q38016673 | ||
| Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy | Q38069375 | ||
| Unravelling mechanisms of p53-mediated tumour suppression | Q38205099 | ||
| Targeting p53-MDM2-MDMX loop for cancer therapy | Q38247168 | ||
| Heat Shock Protein 70s as Potential Molecular Targets for Colon Cancer Therapeutics | Q38847156 | ||
| MDM4 regulation by the let-7 miRNA family in the DNA damage response of glioma cells | Q38869089 | ||
| A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer | Q38910928 | ||
| Siva1 inhibits p53 function by acting as an ARF E3 ubiquitin ligase. | Q39184995 | ||
| Promotion of CHIP-mediated p53 degradation protects the heart from ischemic injury | Q39291547 | ||
| miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation | Q39490746 | ||
| miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia | Q39501936 | ||
| TRIM29 negatively regulates p53 via inhibition of Tip60. | Q39564813 | ||
| Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP. | Q39602480 | ||
| Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination | Q39630352 | ||
| An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity | Q39630646 | ||
| Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53. | Q39723681 | ||
| Axin determines cell fate by controlling the p53 activation threshold after DNA damage | Q39803554 | ||
| High expression of constitutive photomorphogenic 1 (COP1) is associated with poor prognosis in bladder cancer | Q40121054 | ||
| Control of p53 nuclear accumulation in stressed cells | Q40382508 | ||
| p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain | Q40392809 | ||
| The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation | Q40418287 | ||
| Yin Yang 1 is a negative regulator of p53. | Q40542917 | ||
| Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis | Q40750080 | ||
| A Novel Protein Interaction between Nucleotide Binding Domain of Hsp70 and p53 Motif | Q40812082 | ||
| High level of COP1 expression is associated with poor prognosis in primary gastric cancer | Q42410819 | ||
| CHIP-dependent p53 regulation occurs specifically during cellular senescence | Q42478861 | ||
| The C terminus of p53 binds the N-terminal domain of MDM2. | Q42532759 | ||
| UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. | Q42814656 | ||
| The MDM2 RING-finger domain is required to promote p53 nuclear export | Q45301160 | ||
| cop1: a regulatory locus involved in light-controlled development and gene expression in Arabidopsis. | Q46000103 | ||
| Unique complex between bacterial azurin and tumor-suppressor protein p53. | Q46507154 | ||
| A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer | Q46630304 | ||
| Chaperone-dependent stabilization and degradation of p53 mutants | Q46788559 | ||
| Alterations of the p53, Rb and MDM2 genes in osteosarcoma | Q48067523 | ||
| Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. | Q48115514 | ||
| The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry. | Q48287375 | ||
| The Ubiquitin Ligase COP1 Promotes Glioma Cell Proliferation by Preferentially Downregulating Tumor Suppressor p53. | Q48566014 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enzyme | Q8047 |
| phosphoprotein | Q423934 | ||
| transport protein | Q2111029 | ||
| DNA-binding protein | Q2252764 | ||
| nuclear protein | Q16860021 | ||
| neoplasm protein | Q66894191 | ||
| P577 | publication date | 2017-02-17 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Essential Roles of E3 Ubiquitin Ligases in p53 Regulation | |
| P478 | volume | 18 |
| Q91856583 | Amniotic Fluid Cells, Stem Cells, and p53: Can We Stereotype p53 Functions? |
| Q47445829 | Analysis of defective protein ubiquitylation associated to adriamycin resistant cells. |
| Q100751537 | Attenuation of p53 mutant as an approach for treatment Her2-positive cancer |
| Q52723171 | Emerging Non-Canonical Functions and Regulation of p53. |
| Q64122880 | High expression of TRIM36 is associated with radiosensitivity in gastric cancer |
| Q64987440 | High α B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer. |
| Q49189325 | Imaging and kinetics of the bimolecular complex formed by the tumor suppressor p53 with ubiquitin ligase COP1 as studied by atomic force microscopy and surface plasmon resonance. |
| Q100751536 | LINC00355 induces gastric cancer proliferation and invasion through promoting ubiquitination of P53 |
| Q64922459 | Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression. |
| Q42702677 | New Aspects of Vascular Calcification: Histone Deacetylases and Beyond. |
| Q60935673 | Oncogenic Metabolism Acts as a Prerequisite Step for Induction of Cancer Metastasis and Cancer Stem Cell Phenotype |
| Q90317373 | Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors |
| Q92443905 | Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway |
| Q43203015 | Significant association of YAP1 and HSPC111 proteins with poor prognosis in Chinese gastric cancer patients |
| Q49486366 | Targeted photodynamic therapy as potential treatment modality for the eradication of colon cancer and colon cancer stem cells. |
| Q104561842 | Targeting SUMO Signaling to Wrestle Cancer |
| Q92259359 | The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies |
| Q98726035 | The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen |
| Q90480650 | Ubiquitination of P53 by E3 ligase MKRN2 promotes melanoma cell proliferation |
| Q51761242 | p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine. |
| Q42289968 | ρ⁰ Cells Feature De-Ubiquitination of SLC Transporters and Increased Levels and Fluxes of Amino Acids |
Search more.